BridgeBio Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	579.96	502.08	221.9	9.3	77.65	69.72
Revenue Growth (YoY)	355.17%	126.26%	2285.27%	-88.02%	11.38%	745.14%
Cost of Revenue	28.26	20.96	3.88	2.45	3.43	3.11
Gross Profit	551.7	481.11	218.02	6.86	74.21	66.6
Selling, General & Admin	588.76	531.23	288.93	150.59	143.19	192.21
Research & Development	467.16	451.95	506.46	455.71	399.46	451.02
Other Operating Expenses	20.78	21.35	15.61	7.93	43.77	-
Total Operating Expenses	1,077	1,005	811	614.23	586.42	643.23
Operating Income	-525	-523.41	-592.97	-607.37	-512.2	-576.63
Interest Income	20.72	19.85	17.25	18.04	7.54	1.13
Interest Expense	-188.92	-178.24	-99.29	-81.29	-80.44	-46.78
Other Non-Operating Income (Expense)	-36.26	-50.71	132.82	17.37	100.45	35.82
Total Non-Operating Income (Expense)	-204.46	-209.09	50.78	-45.88	27.55	-9.82
Pretax Income	-562.9	-732.5	-542.19	-653.25	-484.65	-586.45
Provision for Income Taxes	0.44	0.44	1.15	-	-	-
Net Income	-729.89	-732.94	-543.35	-653.25	-484.65	-586.45
Minority Interest in Earnings	-8.33	-8.01	-7.59	-10.05	-3.47	-23.92
Net Income to Common	-721.55	-724.93	-535.76	-643.2	-481.18	-562.54
Shares Outstanding (Basic)	193	192	186	163	147	144
Shares Outstanding (Diluted)	193	192	186	163	147	144
Shares Change (YoY)	1.99%	2.93%	14.30%	10.39%	2.16%	22.34%
EPS (Basic)	-3.74	-3.78	-2.88	-3.95	-3.26	-3.90
EPS (Diluted)	-3.74	-3.78	-2.88	-3.95	-3.26	-3.90
Free Cash Flow	-445.12	-447.01	-521.66	-529.03	-424.32	-511.18
Free Cash Flow Per Share	-2.31	-2.33	-2.80	-3.25	-2.88	-3.54
Gross Margin	95.13%	95.82%	98.25%	73.71%	95.58%	95.53%
Operating Margin	-90.52%	-104.25%	-267.22%	-6528.75%	-659.65%	-827.12%
Profit Margin	-125.85%	-145.98%	-244.86%	-7021.94%	-624.16%	-841.20%
FCF Margin	-76.75%	-89.03%	-235.08%	-5686.62%	-546.46%	-733.23%
EBITDA	-519.66	-517.98	-586.9	-600.88	-505.43	-570.79
EBITDA Margin	-89.60%	-103.17%	-264.49%	-6458.95%	-650.93%	-818.74%
EBIT	-525	-523.41	-592.97	-607.37	-512.2	-576.63
EBIT Margin	-90.52%	-104.25%	-267.22%	-6528.75%	-659.65%	-827.12%
Effective Tax Rate	-0.08%	-0.06%	-0.21%	0.00%	0.00%	0.00%

SEC Filings: 10-K · 10-Q